| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Herpesvirus 4, Human | 20 | 2022 | 181 | 2.490 |
Why?
|
| Receptors, Complement 3d | 11 | 2016 | 16 | 1.630 |
Why?
|
| B-Lymphocytes | 9 | 2015 | 569 | 1.020 |
Why?
|
| Epstein-Barr Virus Infections | 5 | 2022 | 91 | 1.000 |
Why?
|
| Thymidine Kinase | 7 | 2010 | 18 | 0.980 |
Why?
|
| Lymphoproliferative Disorders | 2 | 2021 | 39 | 0.880 |
Why?
|
| Viral Matrix Proteins | 5 | 2016 | 49 | 0.780 |
Why?
|
| Herpesvirus 8, Human | 6 | 2005 | 16 | 0.620 |
Why?
|
| Fetal Proteins | 2 | 2012 | 9 | 0.610 |
Why?
|
| Ganciclovir | 6 | 2018 | 18 | 0.540 |
Why?
|
| Virus Attachment | 2 | 2014 | 18 | 0.540 |
Why?
|
| Recombinant Proteins | 4 | 2015 | 700 | 0.520 |
Why?
|
| Antiviral Agents | 6 | 2013 | 321 | 0.470 |
Why?
|
| Sarcoma, Kaposi | 3 | 2005 | 15 | 0.460 |
Why?
|
| Virion | 1 | 2015 | 121 | 0.440 |
Why?
|
| Receptors, Complement 3b | 2 | 2013 | 12 | 0.430 |
Why?
|
| Nuclear Proteins | 2 | 2012 | 773 | 0.430 |
Why?
|
| Antibodies, Neutralizing | 1 | 2015 | 207 | 0.410 |
Why?
|
| Herpesviridae Infections | 3 | 2002 | 26 | 0.400 |
Why?
|
| Antigens, Differentiation | 1 | 2012 | 138 | 0.380 |
Why?
|
| Receptors, Immunologic | 3 | 2012 | 177 | 0.370 |
Why?
|
| Receptors, Complement | 5 | 1990 | 16 | 0.370 |
Why?
|
| Host-Pathogen Interactions | 1 | 2014 | 261 | 0.370 |
Why?
|
| Spleen | 1 | 2012 | 482 | 0.350 |
Why?
|
| Cell Differentiation | 2 | 2016 | 1346 | 0.320 |
Why?
|
| Cell Line | 10 | 2015 | 2038 | 0.300 |
Why?
|
| Acyclovir | 3 | 2010 | 19 | 0.280 |
Why?
|
| Centrioles | 1 | 2007 | 26 | 0.270 |
Why?
|
| Rhadinovirus | 1 | 2005 | 4 | 0.250 |
Why?
|
| Endothelium, Vascular | 2 | 2005 | 175 | 0.240 |
Why?
|
| Protein Binding | 5 | 2015 | 1601 | 0.230 |
Why?
|
| Humans | 37 | 2022 | 62653 | 0.230 |
Why?
|
| Phosphoproteins | 1 | 2005 | 219 | 0.220 |
Why?
|
| Open Reading Frames | 4 | 2005 | 84 | 0.220 |
Why?
|
| Protein Structure, Tertiary | 4 | 2014 | 670 | 0.220 |
Why?
|
| Zidovudine | 2 | 2018 | 12 | 0.200 |
Why?
|
| Bone Marrow Transplantation | 3 | 1998 | 139 | 0.200 |
Why?
|
| Virus Replication | 5 | 2013 | 318 | 0.200 |
Why?
|
| Complement C3d | 1 | 2002 | 2 | 0.200 |
Why?
|
| Antigens, CD | 2 | 2015 | 348 | 0.190 |
Why?
|
| Infectious Mononucleosis | 1 | 2022 | 34 | 0.190 |
Why?
|
| Serogroup | 1 | 2021 | 35 | 0.190 |
Why?
|
| Molecular Sequence Data | 9 | 2007 | 1992 | 0.180 |
Why?
|
| Herpesvirus 1, Human | 2 | 2000 | 82 | 0.180 |
Why?
|
| Cell Adhesion | 2 | 2015 | 207 | 0.170 |
Why?
|
| DNA, Viral | 6 | 2016 | 231 | 0.170 |
Why?
|
| Herpesviridae | 1 | 2000 | 14 | 0.170 |
Why?
|
| Nucleoside-Phosphate Kinase | 1 | 2000 | 6 | 0.170 |
Why?
|
| Immunocompromised Host | 1 | 2000 | 107 | 0.160 |
Why?
|
| Gene Expression Regulation, Viral | 2 | 1998 | 47 | 0.150 |
Why?
|
| Receptors, Virus | 3 | 1990 | 73 | 0.150 |
Why?
|
| Hepatitis B virus | 1 | 1998 | 15 | 0.150 |
Why?
|
| Hepatitis B | 1 | 1998 | 32 | 0.140 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 1998 | 35 | 0.140 |
Why?
|
| Central Nervous System Diseases | 1 | 2018 | 57 | 0.140 |
Why?
|
| Immunohistochemistry | 3 | 2018 | 888 | 0.140 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 1998 | 72 | 0.140 |
Why?
|
| Herpes Zoster | 1 | 2017 | 23 | 0.140 |
Why?
|
| Bacteriophages | 1 | 1998 | 61 | 0.140 |
Why?
|
| Cerebrovascular Disorders | 1 | 2017 | 81 | 0.130 |
Why?
|
| Cell Culture Techniques | 3 | 2016 | 182 | 0.130 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2016 | 206 | 0.130 |
Why?
|
| Antibodies, Viral | 1 | 1998 | 319 | 0.120 |
Why?
|
| Liver | 1 | 2000 | 843 | 0.120 |
Why?
|
| Immunoglobulin G | 2 | 2015 | 463 | 0.120 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2018 | 445 | 0.120 |
Why?
|
| Dependovirus | 1 | 2021 | 694 | 0.120 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 1995 | 60 | 0.120 |
Why?
|
| Neutralization Tests | 1 | 2015 | 122 | 0.120 |
Why?
|
| Mucor | 1 | 1994 | 3 | 0.110 |
Why?
|
| Immunization | 1 | 2015 | 133 | 0.110 |
Why?
|
| Mucormycosis | 1 | 1994 | 10 | 0.110 |
Why?
|
| Amino Acid Sequence | 6 | 2007 | 1594 | 0.110 |
Why?
|
| Neutropenia | 1 | 1994 | 67 | 0.110 |
Why?
|
| Animals | 9 | 2016 | 20579 | 0.110 |
Why?
|
| Mutant Proteins | 1 | 2014 | 105 | 0.110 |
Why?
|
| Tumor Cells, Cultured | 6 | 2002 | 454 | 0.110 |
Why?
|
| Recombination, Genetic | 1 | 1995 | 245 | 0.110 |
Why?
|
| Benzoquinones | 1 | 2013 | 14 | 0.110 |
Why?
|
| Lactams, Macrocyclic | 1 | 2013 | 25 | 0.100 |
Why?
|
| Homeodomain Proteins | 1 | 1995 | 266 | 0.100 |
Why?
|
| Butyrates | 2 | 2006 | 16 | 0.100 |
Why?
|
| Precursor Cells, B-Lymphoid | 1 | 2013 | 8 | 0.100 |
Why?
|
| Antigens, CD19 | 1 | 2013 | 22 | 0.100 |
Why?
|
| K562 Cells | 1 | 2013 | 57 | 0.100 |
Why?
|
| Mice, Inbred BALB C | 1 | 2015 | 893 | 0.100 |
Why?
|
| Transfection | 2 | 2013 | 691 | 0.100 |
Why?
|
| Breast Neoplasms | 1 | 2022 | 1193 | 0.100 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 2 | 1990 | 24 | 0.100 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2013 | 65 | 0.100 |
Why?
|
| Duffy Blood-Group System | 1 | 2012 | 1 | 0.100 |
Why?
|
| Arginine | 2 | 2006 | 122 | 0.100 |
Why?
|
| Protein Kinases | 1 | 2013 | 152 | 0.100 |
Why?
|
| Protein Biosynthesis | 1 | 1995 | 317 | 0.100 |
Why?
|
| Cell Line, Transformed | 3 | 2004 | 99 | 0.100 |
Why?
|
| Genetic Vectors | 1 | 1998 | 850 | 0.100 |
Why?
|
| Virus Internalization | 1 | 2013 | 87 | 0.100 |
Why?
|
| Gene Expression Profiling | 2 | 2014 | 761 | 0.100 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 1994 | 189 | 0.090 |
Why?
|
| Receptors, IgE | 1 | 2011 | 5 | 0.090 |
Why?
|
| Temperature | 1 | 2013 | 309 | 0.090 |
Why?
|
| Gene Expression | 2 | 2014 | 836 | 0.090 |
Why?
|
| T-Lymphocytes | 2 | 2004 | 1005 | 0.090 |
Why?
|
| Enzyme Inhibitors | 1 | 2013 | 373 | 0.090 |
Why?
|
| Immunoglobulin E | 1 | 2011 | 80 | 0.090 |
Why?
|
| Epithelial Cells | 3 | 2016 | 389 | 0.090 |
Why?
|
| Virus Latency | 2 | 2002 | 32 | 0.090 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2004 | 495 | 0.090 |
Why?
|
| Phosphorylation | 3 | 2010 | 937 | 0.080 |
Why?
|
| Cardiovascular Diseases | 1 | 2017 | 832 | 0.080 |
Why?
|
| Viral Proteins | 2 | 2010 | 259 | 0.080 |
Why?
|
| Receptors, Cell Surface | 1 | 2012 | 431 | 0.080 |
Why?
|
| Signal Transduction | 3 | 2016 | 3020 | 0.080 |
Why?
|
| Virus Cultivation | 2 | 2013 | 19 | 0.080 |
Why?
|
| DNA-Binding Proteins | 1 | 1995 | 1184 | 0.070 |
Why?
|
| Cricetinae | 2 | 2007 | 368 | 0.070 |
Why?
|
| Substrate Specificity | 2 | 2000 | 337 | 0.070 |
Why?
|
| Genes, Viral | 1 | 1988 | 57 | 0.070 |
Why?
|
| Mutation | 3 | 2013 | 2573 | 0.070 |
Why?
|
| Base Sequence | 4 | 1998 | 1333 | 0.070 |
Why?
|
| Female | 10 | 2022 | 32478 | 0.070 |
Why?
|
| Cricetulus | 1 | 2007 | 100 | 0.070 |
Why?
|
| Tubulin | 1 | 2007 | 73 | 0.070 |
Why?
|
| CHO Cells | 1 | 2007 | 190 | 0.070 |
Why?
|
| Centrosome | 1 | 2007 | 71 | 0.070 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2007 | 364 | 0.060 |
Why?
|
| Adult | 9 | 2022 | 16623 | 0.060 |
Why?
|
| Biomarkers | 1 | 2012 | 1382 | 0.060 |
Why?
|
| Cell Transformation, Viral | 2 | 2004 | 15 | 0.060 |
Why?
|
| Cells, Cultured | 5 | 2016 | 2154 | 0.060 |
Why?
|
| Antineoplastic Agents | 2 | 2006 | 660 | 0.060 |
Why?
|
| Lymphoma | 1 | 2006 | 101 | 0.060 |
Why?
|
| Neoplasms | 1 | 2016 | 1350 | 0.060 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-3 | 1 | 2005 | 21 | 0.060 |
Why?
|
| Mice | 6 | 2016 | 10802 | 0.060 |
Why?
|
| Cell Cycle | 1 | 2007 | 392 | 0.060 |
Why?
|
| Gene Expression Regulation | 1 | 2012 | 1611 | 0.060 |
Why?
|
| Antibodies, Monoclonal | 4 | 1999 | 866 | 0.060 |
Why?
|
| Endothelium | 1 | 2004 | 21 | 0.060 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2004 | 35 | 0.060 |
Why?
|
| Two-Hybrid System Techniques | 1 | 2004 | 67 | 0.060 |
Why?
|
| 3T3 Cells | 1 | 2004 | 110 | 0.060 |
Why?
|
| Male | 8 | 2018 | 29472 | 0.050 |
Why?
|
| Child | 3 | 2022 | 4436 | 0.050 |
Why?
|
| Lymphatic Vessels | 1 | 2004 | 32 | 0.050 |
Why?
|
| Models, Molecular | 2 | 2011 | 1143 | 0.050 |
Why?
|
| Adenoviridae | 1 | 2004 | 121 | 0.050 |
Why?
|
| Hepatitis C | 2 | 1996 | 151 | 0.050 |
Why?
|
| RNA, Viral | 2 | 2002 | 272 | 0.050 |
Why?
|
| Cytoplasm | 1 | 2004 | 277 | 0.050 |
Why?
|
| HeLa Cells | 1 | 2004 | 532 | 0.050 |
Why?
|
| Green Fluorescent Proteins | 1 | 2004 | 364 | 0.050 |
Why?
|
| Carbohydrate Sequence | 1 | 2002 | 22 | 0.050 |
Why?
|
| Microscopy, Fluorescence | 1 | 2004 | 400 | 0.050 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2002 | 102 | 0.050 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2005 | 324 | 0.050 |
Why?
|
| Microscopy, Electron | 1 | 2002 | 250 | 0.050 |
Why?
|
| Flow Cytometry | 3 | 2005 | 669 | 0.050 |
Why?
|
| Crystallography, X-Ray | 1 | 2002 | 431 | 0.040 |
Why?
|
| Multiple Myeloma | 2 | 1999 | 348 | 0.040 |
Why?
|
| Cloning, Molecular | 3 | 1991 | 383 | 0.040 |
Why?
|
| Transplantation, Homologous | 2 | 1998 | 244 | 0.040 |
Why?
|
| RNA, Messenger | 3 | 1999 | 1528 | 0.040 |
Why?
|
| Herpesvirus 2, Human | 1 | 2000 | 13 | 0.040 |
Why?
|
| DNA Methylation | 1 | 2002 | 291 | 0.040 |
Why?
|
| Deoxyribonucleosides | 1 | 2000 | 3 | 0.040 |
Why?
|
| Diphosphates | 1 | 2000 | 11 | 0.040 |
Why?
|
| Tritium | 1 | 2000 | 22 | 0.040 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2000 | 64 | 0.040 |
Why?
|
| Cell Line, Tumor | 1 | 2004 | 1451 | 0.040 |
Why?
|
| Lung Transplantation | 2 | 1998 | 73 | 0.040 |
Why?
|
| Genes, bcl-2 | 1 | 1999 | 9 | 0.040 |
Why?
|
| Infant, Newborn | 2 | 2000 | 1338 | 0.040 |
Why?
|
| Drug Resistance, Microbial | 2 | 2000 | 48 | 0.040 |
Why?
|
| Stromal Cells | 1 | 1999 | 67 | 0.040 |
Why?
|
| Models, Biological | 1 | 2004 | 1180 | 0.040 |
Why?
|
| Tissue Donors | 2 | 1996 | 153 | 0.040 |
Why?
|
| Prokaryotic Cells | 1 | 1998 | 7 | 0.040 |
Why?
|
| Risk Factors | 2 | 2017 | 5302 | 0.040 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 1999 | 34 | 0.040 |
Why?
|
| DNA Restriction Enzymes | 1 | 1998 | 35 | 0.040 |
Why?
|
| Time Factors | 2 | 2005 | 3740 | 0.040 |
Why?
|
| Logistic Models | 1 | 2022 | 1273 | 0.040 |
Why?
|
| ErbB Receptors | 1 | 1999 | 114 | 0.040 |
Why?
|
| Bone Marrow Cells | 1 | 1999 | 237 | 0.040 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 1998 | 49 | 0.040 |
Why?
|
| Rituximab | 1 | 2018 | 83 | 0.040 |
Why?
|
| Herpes Zoster Ophthalmicus | 1 | 2017 | 6 | 0.040 |
Why?
|
| Organ Transplantation | 1 | 2018 | 54 | 0.030 |
Why?
|
| Viral Nonstructural Proteins | 1 | 1998 | 93 | 0.030 |
Why?
|
| Young Adult | 2 | 2022 | 4633 | 0.030 |
Why?
|
| DNA | 4 | 2005 | 839 | 0.030 |
Why?
|
| DNA Replication | 1 | 1999 | 234 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2018 | 416 | 0.030 |
Why?
|
| Apoptosis | 2 | 1999 | 1066 | 0.030 |
Why?
|
| Dexamethasone | 1 | 2018 | 205 | 0.030 |
Why?
|
| Lymphoma, Large-Cell, Immunoblastic | 1 | 1996 | 1 | 0.030 |
Why?
|
| Blotting, Northern | 3 | 1992 | 149 | 0.030 |
Why?
|
| Biopsy | 1 | 2018 | 429 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2005 | 453 | 0.030 |
Why?
|
| Immunoblotting | 1 | 2016 | 204 | 0.030 |
Why?
|
| In Situ Hybridization | 1 | 2016 | 217 | 0.030 |
Why?
|
| Binding Sites | 1 | 1998 | 900 | 0.030 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2016 | 67 | 0.030 |
Why?
|
| STAT3 Transcription Factor | 1 | 2016 | 70 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2016 | 241 | 0.030 |
Why?
|
| Transplantation, Heterologous | 1 | 2016 | 229 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 4 | 2005 | 515 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2016 | 206 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2016 | 255 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 1998 | 520 | 0.030 |
Why?
|
| DNA Nucleotidyltransferases | 1 | 1995 | 6 | 0.030 |
Why?
|
| Adolescent | 2 | 2022 | 6165 | 0.030 |
Why?
|
| Oncogene Proteins, Viral | 1 | 1995 | 9 | 0.030 |
Why?
|
| VDJ Recombinases | 1 | 1995 | 10 | 0.030 |
Why?
|
| Gene Rearrangement, B-Lymphocyte | 1 | 1995 | 13 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2016 | 519 | 0.030 |
Why?
|
| Tumor Virus Infections | 1 | 1995 | 36 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2016 | 521 | 0.030 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 2005 | 182 | 0.030 |
Why?
|
| Dermatomycoses | 1 | 1994 | 14 | 0.030 |
Why?
|
| Amphotericin B | 1 | 1994 | 23 | 0.030 |
Why?
|
| Interferon-gamma | 1 | 1996 | 567 | 0.030 |
Why?
|
| Opportunistic Infections | 1 | 1994 | 30 | 0.030 |
Why?
|
| Burkitt Lymphoma | 1 | 1995 | 57 | 0.030 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2016 | 303 | 0.030 |
Why?
|
| Survival Rate | 1 | 2016 | 839 | 0.030 |
Why?
|
| Prognosis | 1 | 2018 | 1724 | 0.030 |
Why?
|
| Membrane Proteins | 1 | 1999 | 889 | 0.030 |
Why?
|
| HIV Infections | 1 | 2000 | 962 | 0.030 |
Why?
|
| Pregnancy | 1 | 2000 | 2315 | 0.030 |
Why?
|
| Protein Interaction Mapping | 1 | 2013 | 68 | 0.030 |
Why?
|
| Transcriptome | 1 | 2016 | 380 | 0.020 |
Why?
|
| Middle Aged | 4 | 2018 | 17358 | 0.020 |
Why?
|
| RNA Interference | 1 | 2016 | 618 | 0.020 |
Why?
|
| Viral Load | 1 | 2013 | 229 | 0.020 |
Why?
|
| Transcription, Genetic | 2 | 2002 | 873 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2017 | 2445 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 1998 | 658 | 0.020 |
Why?
|
| Surface Plasmon Resonance | 1 | 2011 | 34 | 0.020 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 1991 | 109 | 0.020 |
Why?
|
| Fibroblasts | 1 | 2013 | 392 | 0.020 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2011 | 86 | 0.020 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2011 | 113 | 0.020 |
Why?
|
| Solubility | 1 | 2011 | 178 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 1992 | 319 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2011 | 231 | 0.020 |
Why?
|
| Antigens, Surface | 1 | 1991 | 196 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2011 | 487 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2011 | 240 | 0.020 |
Why?
|
| Restriction Mapping | 1 | 1990 | 52 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2018 | 1586 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2016 | 898 | 0.020 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2010 | 89 | 0.020 |
Why?
|
| T-Lymphocyte Subsets | 1 | 1991 | 248 | 0.020 |
Why?
|
| Multigene Family | 1 | 1990 | 99 | 0.020 |
Why?
|
| Codon, Nonsense | 1 | 2010 | 58 | 0.020 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2010 | 247 | 0.020 |
Why?
|
| HLA-DR Antigens | 1 | 1989 | 26 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2011 | 411 | 0.020 |
Why?
|
| Immunoglobulin M | 1 | 1989 | 116 | 0.020 |
Why?
|
| Cell Count | 1 | 1989 | 130 | 0.020 |
Why?
|
| Proteins | 1 | 1995 | 749 | 0.020 |
Why?
|
| Rosette Formation | 1 | 1989 | 12 | 0.020 |
Why?
|
| Biological Evolution | 1 | 1990 | 119 | 0.020 |
Why?
|
| Cell Separation | 1 | 1989 | 147 | 0.020 |
Why?
|
| Fatal Outcome | 2 | 2000 | 122 | 0.020 |
Why?
|
| Blotting, Western | 2 | 2005 | 610 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 1989 | 189 | 0.020 |
Why?
|
| Mice, Nude | 1 | 1989 | 271 | 0.020 |
Why?
|
| Species Specificity | 1 | 1989 | 334 | 0.020 |
Why?
|
| Stroke | 1 | 2017 | 1188 | 0.020 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1988 | 80 | 0.020 |
Why?
|
| Cell Division | 1 | 1989 | 450 | 0.020 |
Why?
|
| Fluorescent Dyes | 1 | 1989 | 198 | 0.020 |
Why?
|
| Aged | 2 | 2018 | 14249 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2018 | 5587 | 0.020 |
Why?
|
| Integrin alpha3beta1 | 1 | 2005 | 3 | 0.020 |
Why?
|
| Proteoglycans | 1 | 2005 | 32 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2006 | 463 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2005 | 43 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2005 | 46 | 0.010 |
Why?
|
| Binding, Competitive | 1 | 2005 | 100 | 0.010 |
Why?
|
| Microcirculation | 1 | 2005 | 51 | 0.010 |
Why?
|
| Immunoprecipitation | 1 | 2005 | 126 | 0.010 |
Why?
|
| Amino Acid Motifs | 1 | 2005 | 151 | 0.010 |
Why?
|
| Oligopeptides | 1 | 2005 | 133 | 0.010 |
Why?
|
| Immunosorbent Techniques | 1 | 1984 | 9 | 0.010 |
Why?
|
| Complement C3b | 1 | 1984 | 19 | 0.010 |
Why?
|
| Viral Envelope Proteins | 1 | 2005 | 102 | 0.010 |
Why?
|
| Plasmids | 1 | 2005 | 292 | 0.010 |
Why?
|
| Heparin | 1 | 2005 | 116 | 0.010 |
Why?
|
| Fluorescence | 1 | 1984 | 91 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2005 | 202 | 0.010 |
Why?
|
| Ligands | 1 | 2005 | 417 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 544 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2004 | 318 | 0.010 |
Why?
|
| Cell Movement | 1 | 2005 | 445 | 0.010 |
Why?
|
| Epstein-Barr Virus Nuclear Antigens | 1 | 2002 | 18 | 0.010 |
Why?
|
| Lymphocyte Activation | 2 | 1996 | 759 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2006 | 1932 | 0.010 |
Why?
|
| Cytokines | 1 | 2005 | 933 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2005 | 981 | 0.010 |
Why?
|
| Phenotype | 2 | 1996 | 1191 | 0.010 |
Why?
|
| Vero Cells | 1 | 2000 | 80 | 0.010 |
Why?
|
| Skin Neoplasms | 1 | 2005 | 414 | 0.010 |
Why?
|
| Kidney | 1 | 2002 | 444 | 0.010 |
Why?
|
| bcl-2 Homologous Antagonist-Killer Protein | 1 | 1999 | 11 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2002 | 670 | 0.010 |
Why?
|
| bcl-X Protein | 1 | 1999 | 20 | 0.010 |
Why?
|
| bcl-2-Associated X Protein | 1 | 1999 | 47 | 0.010 |
Why?
|
| Cyclin D | 1 | 1999 | 4 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 1999 | 103 | 0.010 |
Why?
|
| Cyclins | 1 | 1999 | 41 | 0.010 |
Why?
|
| Enzyme Induction | 1 | 1998 | 45 | 0.010 |
Why?
|
| Vincristine | 1 | 1998 | 27 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 1998 | 79 | 0.010 |
Why?
|
| Drug Synergism | 1 | 1998 | 142 | 0.010 |
Why?
|
| Prednisone | 1 | 1998 | 86 | 0.010 |
Why?
|
| Aspergillosis | 1 | 1998 | 40 | 0.010 |
Why?
|
| Doxorubicin | 1 | 1998 | 99 | 0.010 |
Why?
|
| Necrosis | 1 | 1998 | 143 | 0.010 |
Why?
|
| Nuclear Family | 1 | 1996 | 17 | 0.010 |
Why?
|
| Haplotypes | 1 | 1996 | 118 | 0.010 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 1996 | 174 | 0.010 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 1996 | 144 | 0.010 |
Why?
|
| Hepatitis Antibodies | 1 | 1994 | 6 | 0.010 |
Why?
|
| DNA Primers | 1 | 1994 | 292 | 0.010 |
Why?
|
| Hepacivirus | 1 | 1994 | 141 | 0.010 |
Why?
|
| Receptors, Interleukin-6 | 1 | 1992 | 15 | 0.010 |
Why?
|
| Blotting, Southern | 1 | 1991 | 55 | 0.010 |
Why?
|
| CD28 Antigens | 1 | 1991 | 60 | 0.010 |
Why?
|
| B7-1 Antigen | 1 | 1991 | 73 | 0.010 |
Why?
|
| Genes | 1 | 1991 | 90 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 1998 | 1284 | 0.010 |
Why?
|
| Oligonucleotides | 1 | 1991 | 219 | 0.010 |
Why?
|